Answers are grounded in this paper and cite their sources.
Background and Objectives: Clinical outcomes remain heterogeneous in patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer receiving cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. We evaluated the prognostic relevance and incremental prognostic value of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 expression beyond clinical and treatment-related factors. Materials and Methods: This multicenter retrospective study included 568 patients treated with ribociclib- or palbociclib-based therapy between 2019 and 2024. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan–Meier and Cox regression analyses. The incremental prognostic value of ER, PR, and Ki-67 was assessed using nested Cox models with identical baseline clinical covariates and patient samples. Additional spline and exploratory cut-off analyses were performed. Results: Median PFS and OS were 29.23 and 44.43 months, respectively. Liver metastasis was independently associated with shorter PFS (HR 1.77, 95% CI 1.27–2.48; p = 0.001) and OS (HR 1.80, 95% CI 1.24–2.61; p = 0.002). Lung metastasis and prior endocrine therapy were independently associated with shorter PFS, whereas older age and prior endocrine therapy were associated with shorter OS. Although higher PR and lower Ki-67 expression were associated with longer PFS in univariable analyses, higher Ki-67 expression was independently associated with shorter PFS in the multivariable model (HR 1.008, p = 0.025), whereas ER and PR were not significantly associated with PFS or OS. Adding ER, PR, and Ki-67 to baseline clinical models did not significantly improve model fit for PFS (p = 0.087) or OS (p = 0.320). No significant nonlinear associations were identified, and exploratory cut-offs demonstrated limited stability. Exploratory subgroup analyses suggested incremental prognostic value in first-line treatment (p = 0.003), although the treatment-line interaction was not significant. Conclusions: Ki-67 showed an independent association with PFS, although the combined incremental prognostic value of ER, PR, and Ki-67 beyond clinical factors was limited. Further prospective studies are warranted to clarify their clinical utility.
No takes yet. Share an insight, caveat, or question.
Uguztemur et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: